Showing posts with label anorexia. Show all posts
Showing posts with label anorexia. Show all posts

Saturday, October 17, 2026

Genetic Risk For Anorexia May Begin Outside The Brain

A new genetic study reveals that individuals with severe anorexia nervosa are nearly four times more likely to carry rare, damaging mutations in PLIN4, a gene primarily expressed in adipose tissue and skeletal muscle rather than the central nervous system. The discovery challenges the longstanding assumption that anorexia is purely a psychiatric or brain-based condition, highlighting peripheral metabolic dysfunction in lipid storage as a key biological driver………Continue reading…

By: Bethany Mauger

Source:  Neuroscience News

.

Critics:

Anorexia nervosa is an eating disorder characterized by attempts to lose weight by way of starvation. A person with anorexia may exhibit a number of signs and symptoms, the type and severity of which may vary, or be present without being readily apparent. Although anorexia is often recognized by physical indicators, it is a mental disorder that can occur at any body weight; in cases where body mass index (BMI) remains at a healthy level in adults, but other symptoms are present, the diagnosis may be atypical anorexia nervosa instead.

Anorexia, and the associated malnutrition from self-imposed starvation, causes complications in every major organ system in the body. It can cause permanent changes in the brain due to a lack of essential nutrients in the body. Hypokalemia, a drop in the level of potassium in the blood, is a sign of anorexia: a significant drop in potassium can cause abnormal heart rhythms, constipation, fatigue, muscle damage, and paralysis.

Interoception involves the conscious and unconscious sense of the internal state of the body, having an important role in homeostasis and regulation of emotions. Aside from noticeable physiological dysfunction, interoceptive deficits also prompt individuals with anorexia to concentrate on distorted perceptions of multiple elements of their body image. This exists in both people with anorexia and in healthy individuals, due to impairment in interoceptive sensitivity and interoceptive awareness.

Aside from weight loss and external appearance, people with anorexia may also report abnormal bodily functions, such as indistinct feelings of fullness.[56] This is due to miscommunication between internal signals of the body and the brain. Due to impaired interoceptive sensitivity, powerful cues of fullness may be detected prematurely in highly sensitive individuals, which add to decreased calorie consumption and generate anxiety surrounding food intake in anorexia patients.

People with anorexia also report difficulty identifying and describing their emotional feelings, and an inability to distinguish emotions from bodily sensations in general (known asalexithymia), likely due to the miscommunication of signals within the body. Interoceptive awareness and emotion are deeply intertwined. Anorexia patients also exhibit emotional regulation difficulties that ignite emotionally-cued eating behaviors, such as restricting food or excessive exercising.

Impaired interoceptive sensitivity and interoceptive awareness can lead anorexia patients to adapt distorted interpretations of weight gain that are cued by physical sensations related to digestion (e.g. fullness). Combined, these interoceptive and emotional elements could together trigger maladaptive and negatively reinforced behavioral responses that contribute to the maintenance of anorexia.

In addition to metacognition, people with anorexia also have difficulty with social cognition, including interpreting others’ emotions and demonstrating empathy. Abnormal interoceptive awareness and interoceptive sensitivity shown through all of these examples have been observed so frequently in anorexia that they have become key characteristics of the illness.

Both prenatal and perinatal obstetric complications may factor into the development of anorexia nervosa, such as preterm birth, maternal anemia, diabetes mellitus, preeclampsia, placental infarction, and neonatal heart abnormalities. Neonatal complications may also have an influence on harm avoidance, one of the personality traits associated with the development of anorexia.

Neuroendocrine dysregulation—the altered signaling of peptides that facilitate communication between the gut, brain and adipose tissue, such as ghrelin, leptin, neuropeptide Y and orexin—may contribute to the pathogenesis of anorexia nervosa by disrupting regulation of hunger and satiety. People with gastrointestinal diseases may be more at risk of developing disorders of eating practices than the general population, principally with restrictive eating disturbances.

An association of anorexia with celiac disease has been found. Individuals with good dietary management may develop anxiety, food aversion, and eating disorders because of concerns around cross contamination of their foods. Some authors suggest that medical professionals should evaluate the presence of unrecognized celiac disease in all people with an eating disorder, especially if they present any gastrointestinal symptoms .

Such as decreased appetite, abdominal pain, bloating, distension, vomiting, diarrhea or constipation, weight loss, or growth failure. It is also recommended to routinely ask celiac patients about weight or body shape concerns, and dieting or vomiting for weight control to evaluate the possible presence of an eating disorder, especially in women.

,Genetic ,Anorexia ,MentalHealthAwareness ,BodyPositivity ,EatingDisorders ,HealthJourney ,GeneticResearch ,AnorexiaAwareness ,MentalHealthMatters ,GeneticFactors ,RecoveryIsPossible ,Wellness ,SelfLove ,HealthCommunity ,FightAgainstAnorexia ,AnorexiaRecovery ,GeneticInfluence ,SupportAndRecovery ,HopeInRecovery

 

Monday, April 14, 2025

Why These Investment Firms Bet $400 Million On A Chinese Ozempic Rival

 Albie Colantonio for Forbes

In the summer of 2023, Dr. Amir Zamani, a 42-year-old Johns Hopkins trained physician who is a partner on Bain Capital’s life sciences team in Boston, was obsessed with obesity drugs. Ozempic, the blockbuster injectable for type 2 diabetes from Novo Nordisk, was taking America by storm, on pace to generate some $14 billion in revenue that year for the Danish pharmaceutical giant…….Continue reading……

By Amy Feldman Source: Forbes . Critics:

Some compounded versions have been found to contain salts of semaglutide including the sodium and the acetate in an attempt to avoid the patent of the base semaglutide product. These are not evaluated for safety and effectiveness by and thus are considered not shown to be safe or effective by the US Food and Drug Administration (FDA).

A 2014 meta-analysis found that semaglutide may be effective in lowering liver enzymes (transaminitis) and improving certain radiologically observed features of metabolic dysfunction–associated steatotic liver disease. French national health care insurance system database had previously suggested 1–3 years use of glucagon like peptide-1 receptor agonists like exenatide, liraglutide and dulaglutide may be linked with increased occurrence of thyroid cancer. Semaglutide belongs to the same family of medicine.

A meta-analysis involving data from 37 randomized controlled trials and 19 real world studies (46,719 patients) showed that semaglutide use over 18 months was not associated with increased risks of any cancer, supported by a high grade of evidence. In July 2023, the Icelandic Medicines Agency reported two cases of suicidal thoughts and one case of self-injury of users of the injection, prompting a safety assessment of Ozempic, Wegovy, Saxenda, and similar drugs.

In January 2024, a preliminary review conducted by the FDA confirmed no evidence had been found to suggest that the medicine causes suicidal thoughts or actions. Semaglutide has shown potential to reduce interest in alcohol consumption among users. Scientists speculate that semaglutide may influence brain regions involved in addiction and appetite regulation, although the exact mechanisms remain under study.

Animal research has indicated that drugs similar to semaglutide can reduce alcohol intake. Semaglutide and similar drugs, such as dulaglutide and liraglutide, have been used to treat binge eating disorder (BED), as they can successfully minimize obsessive thoughts about food and binging urges.

Dietary supplements, foodstuffs, or programs for weight loss are heavily promoted through advertisements in print, on television, and on the internet. The US Food and Drug Administration recommends caution with use of these products, since many of the claims of safety and effectiveness are unsubstantiated, and many of the studies purporting to demonstrate their effectiveness are funded by the manufactures and suffer a high degree of bias.

Individuals with anorexia nervosa or bulimia nervosa, and some athletes, try to control body weight with diet pills, laxatives, or diuretic medications, although the latter two generally have no impact on body fat and only cause short-lived weight-loss through dehydration. Both diuretics and laxatives can cause electrolyte abnormalities which may cause cognitive, heart, and muscle problems, and can be fatal.

Canadian clinical practice 2006 guidelines state that there is insufficient evidence to recommend in favor of or against using herbal medicine, dietary supplements or homeopathy against obesity. Some botanical supplements include high dosages of compounds found in plants with stimulant effects including yohimbine and higenamine.

Caffeine, coffee and green tea can suppress appetite (the hormone ghrelin) and decrease caloric intake (food consumption). It can also cause beneficial changes in fat metabolism or lipolytic actions. According to a review, habitual intake of 3 to 4 cups of coffee appears to be safe and to be associated with the most robust beneficial effects.

Thermogenic actions and, in the case of the caffeinated drink mate (yerba maté), prolonged gastric emptying time may also play a role. Some anti-obesity medications can have severe, even, lethal side effects, fen-phen being a famous example. Fen-phen was reported through the FDA to cause abnormal echocardiograms, heart valve problems, and rare valvular diseases.

 

One of, if not the first, to sound alarms was Sir Arthur MacNalty, Chief Medical Officer (United Kingdom). As early as the 1930s, he warned against the use of 2,4-Dinitrophenol as an anti-obesity medication and the injudicious and/or medically unsupervised use of thyroid hormone to achieve weight reduction. The side effects are often associated with the medication’s mechanism of action.

In general, stimulants carry a risk of high blood pressure, faster heart rate, palpitations, closed-angle glaucoma, drug addiction, restlessness, agitation, and insomnia. Another medication, orlistat, blocks absorption of dietary fats, and as a result may cause oily spotting bowel movements (steatorrhea), oily stools, stomach pain, and flatulence.

A similar medication designed for patients with Type 2 diabetes is Acarbose; which partially blocks absorption of carbohydrates in the small intestine, and produces similar side effects including stomach pain and flatulence…

National Institute for Health and Clinical Excellence. Clinical guideline 43: Obesity: The prevention, identification, assessment and management of overweight and obesity in adults and children. London, 2006.

“WIN – Publication – Prescription Medications for the Treatment of Obesity”. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Food and Drug Administration. Archived from the original on 18 January 2017. Retrieved 16 December 2019.

FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014″. FDA. 21 June 2021. Retrieved 19 July 2022.

Drug interventions for the treatment of obesity in children and adolescents”. The Cochrane Database of Systematic Reviews.

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians”. Annals of Internal Medicine

Guidance for Industry Developing Products for Weight Management”. Food and Drug Administration.

Evekeo Prescribing Information” (PDF).

Effects of GLP-1 on appetite and weight”. Reviews in Endocrine & Metabolic Disorders.

The return of rainbow diet pills”. American Journal of Public Health.

Leave a Reply

Turn The Latest AI Trend Into a Brand-New Income Stream With GPT-6 Astra AI Mastery With PLR

You don’t have to create everything from scratch. Scripting, recording, writing and designing can take weeks. By the time most people finish...